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Abstract: Despite the introduction of more than 15 third generation antiepileptic drugs to the market 
from 1990 to the moment, about one third of the epileptic patients still suffer from refractory to 
intractable epilepsy. Several hypotheses seek to explain the failure of drug treatments to control epilepsy 
symptoms in such patients. The most studied one proposes that drug resistance might be related with 
regional overactivity of efflux transporters from the ATP-Binding Cassette (ABC) superfamily at the 
blood-brain barrier and/or the epileptic foci in the brain. Different strategies have been conceived to address the transporter 
hypothesis, among them inhibiting or down-regulating the efflux transporters or bypassing them through a diversity of 
artifices. Here, we review scientific evidence supporting the transporter hypothesis along with its limitations, as well as 
computer-assisted early recognition of ABC transporter substrates as an interesting strategy to develop novel antiepileptic 
drugs capable of treating refractory epilepsy linked to ABC transporters overactivity.  
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1. INTRODUCTION 
1.1. Drug Resistant Epilepsy: Definition and Current 
Explanations 
 Epilepsy is the most frequent chronic brain disorder, 
affecting about 50 million people worldwide [1]. While drug 
therapy is the treatment of choice and can successfully treat 
(i.e. provide sustained seizure freedom) about 70% of people 
with epilepsy [1], the remaining 30% of the patients suffer 
from drug resistant, refractory or intractable epilepsy [2], i. e. 
the failure to achieve seizure freedom through adequate trials 
of two tolerated appropriately chosen antiepileptic drug 
(AED) schedules [3] (note that a clear, universal definition 
of refractory epilepsy will be fundamental to approach the 
limitations of the neurobiological explanations to refractory 
epilepsy later in this article). This scenario has not changed 
substantially in spite of the introduction of more than 15 
third generation AEDs from 1990 to the moment [4], a fact 
that has led to a decrease in the industrial interest in the 
development of new compounds for epilepsy [5].  
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 Biological mechanisms underlying drug resistant epilepsy 
have not been fully elucidated yet [5], though there exist to 
the day five hypotheses that try to explain the nature of this 
phenomenon: the transporter hypothesis [6, 7], the target 
hypothesis [7, 8], the neural network hypothesis [9], the gene 
variant hypothesis [10] and the intrinsic severity hypothesis 
[11]. Historically speaking, the transporter and target 
hypotheses have been conceived earlier and have therefore been 
more extensively explored from an experimental viewpoint.  
 The transporter hypothesis sustains that drug resistant 
epilepsy may be a consequence of the local overactivity of 
ATP-Binding Cassette (ABC) transporters at the blood-brain 
barrier (BBB) and/or the epileptic foci. A more detailed 
overview on the evidence and limitations of this hypothesis 
is provided in the next subsection. The target hypothesis 
proposes that the reduced sensitivity to AEDs might be 
linked to acquired modifications in the structure and/or 
functionality of AED targets. While some years back 
constitutive alterations of drug transporters or targets were 
also considered within the scope of the transporter and target 
hypothesis, respectively [8, 12], leading experts in the field 
now seem to prefer to categorize intrinsic alterations (genetic 
variants) of drug targets within the gene variant hypothesis 
[5]. The gene variant hypothesis, however, also covers other 
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possible genetic causes of drug resistance (e.g. polymorphic 
variants of drug biotransformation enzymes). In the frame of 
this novel classification scheme, only acquired modifications 
in drug transporters or targets would be contained by the 
transporter or target hypothesis. Though at first sight this 
distinction may appear as a trivial classification problem, the 
nature of the pharmacokinetic or pharmacodynamic alteration 
could have a profound impact on the clinical approach to the 
drug resistance issue. While a genetic cause of 
pharmacoresistance might currently be detected through 
simple diagnostic tests even before starting the treatment, 
acquired modifications linked to the pathophysiology of the 
disease are more difficult to prove and still require more 
invasive procedures (e.g. surgery resection). Recently, a 
possible role of epigenetics in drug resistance epilepsy has 
also been suggested (establishing a sixth hypothesis for 
refractory epilepsy that might serve to expand the biological 
basis to other previous hypotheses such as the transporter and 
the target hypotheses), though to the moment the experimental 
basis supporting this mechanism remains scarce [13].  
 The neural network hypothesis maintains that recurrent 
episodes of excessive neural activity lead to plastic 
alterations and remodeling of the neural network; abnormal 
networking might in turn relate to the drug resistance 
phenomena. The hypothesis is supported by the fact that 
surgical resection of the seizure focus frequently results in 
seizure freedom [5]. As a matter of fact, epilepsies of 
structural cause are linked to drug resistance and abnormal 
brain imaging, and a good surgical outcome (seizure 
freedom) is associated to complete surgical resection of the 
epileptic focus or lesion, pre-surgical presence of lesions in 
MRI scans and the network complexity [14]. The differences 
between the alterations in brain plasticity in responsive and 
non-responsive patients are yet to be elucidated [9].  
 At last, the intrinsic severity hypothesis relies on 
epidemiologic studies showing that the single most 
important factor linked to the prognosis of epilepsy is the 
number of seizures at the epilepsy onset. Again, the 
biological basis of disease severity are however no fully 
understood to the moment [15], so currently the influence of 
the intrinsic severity hypothesis on treatment choice or 
treatment development is limited.  
 It has been pointed out that none of the previous 
hypotheses provides a full or universal explanation to non-
responsive patients with epilepsy: a given hypothesis might 
be applicable to a particular subgroup of patients or, 
alternatively, some patients could require multiple 
hypotheses to explain their non-responsiveness [5, 12, 16]. 
The network hypothesis seems so far as the more holistic 
explanation to drug resistance, since some of the other 
explanations (e.g. the target hypothesis) could be applied in 
its context [5]. It is worth underlining that the treatment 
approach should be highly dependent on the drug resistance 
mechanisms present in a particular patient.  
1.2. Strengths and Weaknesses of the Transporter 
Hypothesis of Drug Resistant Epilepsy 
 In eukaryotes, ABC transporters are transmembrane 
efflux transporters (they export their substrates from the cell) 
and they are characterized by broad-substrate specificity/ 
polispecificity [17, 18]. They are preferentially expressed in 
barrier tissues (gut, BBB) and elimination organs (liver, 
kidneys), limiting the absorption and biodistribution and 
favoring the elimination of their substrates. Besides their role 
in the traffic of physiologic compounds (e.g. cholesterol or 
amyloid beta) they also take part in multi-drug resistance 
phenomena or pathogenesis in a diversity of disorders [18-
20]. Though most of the research on ABC transporters has 
focused on the first historically identified member of the 
superfamily (P-glycoprotein, Pgp or P-gp or ABCB1 or 
MDR1), attention of the scientific and medical community 
has more recently been given to other members, prominently 
MRPs (ABCCs) and Breast Cancer Resistance Protein 
(BCRP, ABCG2).  
 Preclinical validation of the transporter hypothesis for 
drug resistant epilepsy has been achieved, since drug 
resistance in animal models of refractory epilepsy has been 
reverted by co-administration of ABC transporters inhibitors. 
The first steps towards a proof of concept of the potential 
role of ABC transporters was delivered by Potschka et al. 
back in 2001 [21]. Using in vivo microdialysis in rats, the 
authors showed that the levels of carbamazepine in the 
extracellular fluid of the cerebral cortex could be enhanced 
through local perfusion of Pgp inhibitor verapamil and 
MRP1/2/5 inhibitor probenecid. Some time later, the same 
researchers proved that co-administration of probenecid (50 
mg/kg) and phenytoin (6.25 mg/kg) resulted in a clear 
increase of phenytoin anticonvulsant effect in electrically 
kindled rats (a 90% increase in the threshold for generalized 
seizures) [22]. Neither 50 mg/kg probenecid nor 6.25 mg/kg 
phenytoin exerted significant anticonvulsant effect when 
given alone. It was discussed that such raise in the seizure 
threshold was unlikely to result from additive effects of the 
chosen subanticonvulsant doses. Interestingly, the inhibition 
of MRP2 (which is located in the apical membrane of 
endothelial cells and thus opposes to drug penetration in the 
brain) results in a significant increase of drug levels in the 
brain which was not secondary to alterations in peripheral 
drug pharmacokinetics. Similar results were later obtained in 
the focal pilocarpine model of limbic seizures [23]: while ip 
administration of oxcarbazepine 100 mg/kg to rats did not 
prevent seizures, co-administration of verapamil or 
probenecid resulted in complete protection. The severity of 
pilocarpine-induced seizures severity was not affected by 
perfusion of any of the inhibitors alone. Though highly 
valuable, this initial works had two important limitations: a) 
the use of first-generation, weak and unspecific modulators 
of ABC transporters and; b) experiments were performed on 
animal groups with no discrimination between responder and 
non-responder subgroups. The first issue was later solved 
through the use of third-generation, specific inhibitor of Pgp 
tariquidar. Van Vliet et al. used a chronic epileptic rat model 
and showed that, while phenytoin alone did not achieve 
complete suppression of spontaneous seizures, co-
administration of phenytoin and tariquidar led to an almost 
complete seizure control [24]. Inhibition of Pgp by tariquidar 
increased the phenytoin brain-to-plasma ratio; it was also 
shown that the maximal administered doses of tariquidar did 
not exert anticonvulsant activity per se. The effect of co-
administration of tariquidar on seizure control reverted after 
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four days, suggesting that tolerance to tariquidar was 
developed. Definitive preclinical proof of concept was 
obtained by co-administration of tariquidar to epileptic drug 
resistant animals associated to up-regulated Pgp expression 
[25]. The key innovation in this study was the introduction 
of a protocol to discriminate responsive and nonresponsive 
animals to phenobarbital (Fig. 1). When co-administering 
tariquidar, five out of six non-responders became seizure-
free or displayed a reduction in seizure of at least 50%. 
Similar results were obtained in the 3-mercaptopropionic 
acid model of refractory epilepsy, which is associated to Pgp 
upregulation at the BBB, astrocytes and neurons [26]. While 
3-mercaptopropionic acid epileptic rats showed significantly 
lower hippocampal phenytoin concentrations compared to 
the control group, pre-treatment of such animals with the 
Pgp inhibitor nimodipine led to enhanced hippocampal 
phenytoin bioavailability (the drug hippocampal 
bioavailability was, in fact, even higher than in control 
animals, suggesting other possible interactions between 
phenytoin and nimodipine). It should be noted, however, that 
verapamil add-on therapy failed to enhance seizure control in 
a study on 11 phenobarbital resistant dogs; in fact, some 
animals showed a tendency to worsening of seizure control 
[27]. These results highlight the potential importance of 
inter-species differences and the necessity to validate the 
transporter hypothesis using appropriate clinical trials. Even 
so, clinical proof-of-concept remains elusive, as will be 
discussed next.  
 Regarding clinical data, plenty of evidence has 
accumulated over the years showing high expression levels 
of ABC transporters at the neurovascular unit of non-
responder patients [28-35]. It should be commented, 
however, that most of these studies compared brain samples 
from patients with intractable epilepsy that had been 
subjected to surgical removal of the epileptic focus with 
specimens of human brain with no history of seizures. While 
brain tissue from epileptic drug-responsive patients would be 
a more suitable control, such control samples are usually 
unavailable since the invasive procedure to attain them is 
ethically unacceptable in responsive epileptic patients. This 
limitation has fortunately been overcome in more recent 
studies using positron emission tomography (PET) scans [36, 
37] which showed that the plasma-to-brain transport rate 
constant K1 for [11C]verapamil and (R)- [11C]verapamil tends 
to be lower in different brain regions of drug resistant 
epileptic patients compared with seizure-free patients and 
healthy individuals. Whole brain K1 was increased in both 
healthy subjects and pharmacoresistant patients after 
tariquidar administration. The results from the study using 
(R)-[11C]verapamil [36] are particularly relevant since some 
of the limitations emerging from the diversity of factors 
affecting radiotracer kinetics [38, 39] are addressed. These 
are extremely important steps toward validation of the 
transporter hypothesis, though definite proof would require 
reversal of drug resistance (improvement in seizure control) 
after blocking ABC transporters. Anecdotal cases of 
refractory patients who have shown improvement when 
AEDs were co-administered with verapamil have been 
reported [40-43], but it is not clear yet if the observed results 
could be a consequence of the intrinsic anticonvulsant 
activity of verapamil (e.g. through modulation of calcium 
influx in neurons) or another effect of this drug on the AED 
pharmacokinetics. More recently, a pilot study was 
conducted on seven children with drug resistant epilepsy 
[44]. The patients received verapamil as add-on therapy to 
baseline AED. Three individuals with genetically determined 
Dravet syndrome showed a partial response to adjunctive 
verapamil; another patient with Dravet syndrome but no 
known mutation showed partial seizure control during 13 
months followed by seizure worsening. Two subjects with 
structural epilepsy and one with Lennox-Gastaut displayed 
no improvement. Though the number of patients that took 
part in the study is very limited, the results are in line with 
the idea that some therapeutic interventions might be more 
effective in certain subgroups of non-responders. Later, a 
double-blind, randomized, single-centered trial (initial 
sample size = 22) showed mild benefits of verapamil in 
comparison to placebo as add-on therapy for refractory 
 
 
Fig. (1). Schematic illustration of selection of drug refractory rats from BLA model by prolonged administration of phenobarbital. SE= status 
epilepticus. BLA= prolonged electrical stimulation of the basolateral amygdala. 
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epilepsy for a subset of the participants [45]. Randomized 
multi-centered control trials and studies addressing the effect 
of selective inhibitors of P-gp with no intrinsic activity are 
still necessary to gain definitive clinical evidence for the 
transporter hypothesis. Regarding the association between 
genetic variants of ABC transporters and drug resistant 
epilepsy, studies outcomes are controversial or sometimes 
inconclusive; while former meta-analysis failed to establish 
and association between ABCB1 variants and refractory 
epilepsy [46], subgroup analysis in more recent ones have 
suggested associations in Asian and Caucasian subjects [47-
49], thus contributing to the validity of the hypothesis.  
 The main argument against the transporter hypothesis 
seems to be that not all AEDs are in fact Pgp substrates. 
Although apparently conflictive evidence exists regarding 
which AEDs are substrates and which are not [50, 51], 
results are highly dependent on the experimental setting, 
including type of assay (in vivo, ex vivo or in vitro, human 
versus animal models, concentration equilibrium transport 
assay or non-equilibrium conditions). Still, it seems safe to 
say that at least some AEDs are unlike Pgp substrates. Some 
considerations should be taken into account to reach a 
conclusion regarding the assigned category (substrate or 
non-substrate). Possible inter-species variability in substrate 
specificity should not be excluded. In relation to in vitro 
permeability assays, bi-directional transport assays in 
presence and absence of a selective Pgp inhibitor might lack 
sensitivity since directional transport might be masked by the 
contribution of passive diffusion. The magnitude of this 
effect depends on the substrate assayed concentration/s, the 
transporter expression levels in the cell culture, the affinity 
between the drug and the transporter and the 
physicochemical features of the test drug (e.g. permeability), 
among other factors [52]. Starting the assay with identical 
concentrations of drug on both sides of the cell monolayer 
(concentration equilibrium transport assay, CETA) removes 
the concentration gradient, eliminating net diffusion and 
enhancing the assay sensitivity [53, 54]. 
 Even if it has been demonstrated in appropriate models 
that some available AEDs are not Pgp substrates, does this 
undermine the transporter hypothesis as explanation drug 
resistance in epilepsy? Not necessarily. First, Pgp is one 
among many other efflux transporters possibly involved in 
refractory epilepsy. While most of the studies to determine 
the directional transport of AEDs have focused on Pgp, some 
of the antiepileptic agents are recognized and translocated by 
other members of the ABC superfamiliy. For instance, the 
role of ABCG2 in the drug resistance phenomena to AEDs 
might have been overlooked: while previous work seemed to 
suggest that several AEDs were not recognized by ABCG2 
[49], more recent studies using double knock-out 
Mdr1a/1b(−/−)/Bcrp(−/−) mice and the CETA model 
suggest otherwise [55, 56]. It is also relevant to note that 
proteomics studies have shown ABCG2 as the transporter 
with highest basal expression levels at the BBB of healthy 
subjects [57, 58], which underlines the convenience of 
assessing recognition by other ABC transporters apart from 
Pgp when designing novel AEDs. Furthermore, due to the 
partial overlapping of the substrate specificity of different 
members of the superfamiliy (which together with reported 
co-expression and co-localization patterns points to a 
cooperative role in the disposition of common substrates) 
[59-61], the role of a certain ABC transporter might be 
concealed due to the function of others, requiring complex 
models to study the phenomena. The difficulties to quantify 
the levels of expression of a given transporter in different 
regions of the brain of an epileptic patient who has not been 
subjected to a surgical intervention/resection, and the 
uncertainties regarding the ability of experimental models to 
reflect the absolute and relative expression levels of the 
different ABC efflux transporters at the epileptic foci and the 
BBB (expression levels which might well be highly patient-
dependent and highly dynamic) contribute to the difficulty of 
assessing unequivocally the influence of a given transporter 
in the regional AED bioavailability in the brain.  
 Apart from the need to contemplate the separate and 
concerted contributions of different ABC transporters to the 
efflux of AEDs from CNS, the current definition of 
refractory epilepsy itself suggest that the transporter 
hypothesis may hold even if known AEDs are recognized by 
ABC transporters. Since the definition indicates that a 
patient should be considered unresponsive after failure of 
two well tolerated and appropriately chosen and used AED 
trials, the key to the preceding reasoning lies in what is 
considered an appropriate drug choice. The definition of 
drug resistant epilepsy weakens the transporter hypothesis if 
and only if one of the two appropriate therapeutic 
interventions was in fact a non-substrate for ABC transporters. 
Presently, in absence of definitive clinical proof of the 
transporter hypothesis, it is not standard protocol to try at 
least one AED not recognized by ABC transporters; thus, to 
the moment the quality of substrate or non-substrate is not 
related to the appropriateness. If the transporter hypothesis 
were validated in at least a subgroup of the unresponsive 
patients, then a method for patient selection capable of 
identifying patients that may benefit from therapeutic 
strategies targeting efflux transport will be necessary; 
furthermore, patient selection should also be considered 
when designing clinical trials to study the clinical relevance 
of the transporter-associated resistance [62], excluding other 
sources of drug resistance as possible confounders.  
1.3. Possible Therapeutic Solutions to Transported-
mediated Refractory Epilepsy  
 There are a number of possible therapeutic solutions that 
could be and are being explored in consequence with the 
transporter hypothesis.  
 Inhibition of ABC transporters by adding on transporter 
inhibitors has been already proposed as a possible therapeutic 
solution to efflux-mediated drug resistant cancer. However, 
clinical trials to support this approach have so far been 
disappointing [16, 18, 62 and refs therein] owing to severe 
safety issues. The reader should bear in mind the physiologic 
role of ABC transporters as a general detoxification 
mechanism and their involvement in the traffic of endogenous 
substrates, which discourages the use of add-on inhibitors in 
the context of long-term drug treatments (such as the used in 
epilepsy). The potential effects of such inhibitors in the 
pharmacokinetics of other drugs should also be considered in 
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a polymedication scenario, due to the high probability of 
adverse drug interactions. The connection between ABC 
transporter dysfunction and neurodegenerative diseases such 
as Parkison’s and Alzheimer’s diseases can be quoted as an 
example of the potential risk posed by chronic inhibition of 
this efflux systems [63-65]. Moderate or week inhibitors of 
ABC transporters thus emerge as possible solutions. So do 
therapeutic agents directed to the signaling cascade that 
regulates efflux transporters expression [62]. Such option 
might prove useful to prevent or ameliorate drug- or disease-
induced up-regulation of transporters function, e.g. through 
activation of nuclear receptors or through pro-inflammatory 
signals, respectively. An extensive review on such 
approaches can be found in the excellent articles from 
Potschka [62, 66].  
  In the second place one may mention the use of a Trojan 
horse stratagem to deliver therapeutic levels of the ABC 
transporters substrates to the epileptic focus, avoiding the 
recognition of the efflux pumps. Particulate delivery systems 
(mainly, pharmaceutical nanocarriers) can be included in this 
category [67, 68]. Interestingly, this approach allows 
encapsulating efflux pump substrate AEDs of clinical use 
within advanced delivery systems. Thus, the transference of 
such technologies to the clinical practice is expected to be 
more straightforward than other alternatives described in this 
section. Provided that safe delivery vectors are used, since 
the safety and efficacy of the pharmaceutical active 
ingredient have already been demonstrated, this strategy 
implies better chances of surviving clinical trials. In line with 
the preceding approach we can mention the design of 
prodrugs of AEDs either lacking affinity for ABC transporters 
or displaying affinity for influx transporters that could 
compensate the efflux pumps influence on BBB permeability. 
Though a diversity of prodrugs of approved AEDs have been 
conceived, the interaction of most of them with efflux pumps 
has not been assessed yet [66, 68]. 
 The design of novel AEDs which are not recognized by 
ABC transporters and the early screening during drug 
development to discard substrates (thus considering efflux 
pumps as anti-targets) constitute interesting but underexplored 
alternative solutions. A scheme illustrating the different 
strategies overviewed in this subsection is presented in  
(Fig. 2). The following section will overview recent studies 
focused on this last approximation.  
 Screening during CNS drug development guarantees that 
high affinity substrates of BBB efflux transporters are not 
selected as lead compounds.  
2. IN SILICO SCREENING TO FIND THERAPEUTIC 
SOLUTIONS TO DRUG RESISTANT EPILEPSY 
 The Medicinal Chemistry group from the National 
University of La Plata has implemented a cascade protocol 
integrating in silico (ligand- and structure-based), in vitro 
and in vivo models to detect potential new treatments for 
efflux transporter-associated refractory epilepsy. The 
protocol starts with high-throughput cost-efficient in silico 
screening tools and progressively advances to more 
expensive models with lower throughput, ending in 
preclinical models of drug-resistant epilepsy that will not be 
discussed in detail here. A schematic flux diagram of the 
protocol is displayed in (Fig. 3). Each step is covered 
separately under the correspondent subheading, below these 
lines. 
 
 
 
Fig. (2). Summary of the therapeutic strategies overviewed in 
section 1.3. 
 
 
 
Fig. (3). Cascade protocol to screen for potential therapeutics for 
drug resistance epilepsy related to P-gp upregulation. 
 
2.1. In silico Models to Identify ABC Transporters 
Substrates. Applications to AEDs Screening  
 A large number of computational models to detect 
potential substrates of ABC transporters have been reported, 
from pharmacophores to machine learning algorithms [69-71 
and refs therein]. Many of those models have been derived 
from structural homologous series, thus being capable of 
making accurate predictions in their local chemical space but 
lacking general applicability. Others lack experimental 
validation of the predictive ability. While initially attention 
was drawn to Pgp and, particularly, the prediction of 
inhibitory activity, most recently, as the relevance of other 
efflux pumps is recognized and the inhibitors entering 
clinical trials fail, the focus has been gradually shifting 
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towards other members of the ABC superfamily and the 
prediction of transport [71, 72]. Most of these models show 
accuracy around 80%, which reflects the challenge posed by 
the multiplicity of binding mechanisms, the related 
polyspecificity and the high experimental variability of 
available data; such demanding proposition for modeling has 
led some authors to propose ensemble learning as a potential 
solution [70, 73, 74]. The reports of applications of such 
models to the selection of novel AEDs as potential treatment 
for drug resistant epilepsy are, to date, scarce.  
 In this regard, back in 2011 Di Ianni and colleagues 
reported a 3-model ensemble of 2D QSAR classifiers 
capable of differentiating P-gp substrates from non-
substrates [75]. For this purpose, a 250-compound dataset 
including 104 P-gp substrates and 146 non-substrates was 
compiled from literature. Random sampling was applied to 
split such dataset into a 125-compound training set and a 125-
compound test set. Linear discriminant analysis was 
conducted to select conformation-independent models from 
different subsets of Dragon descriptors. Later, simple data 
fusion schemes were used to combine individual models in 
order to optimize specificity. Receiving Operating 
Characteristic curves were applied to compare model 
performance and to select the best data fusion scheme. The 
ensemble showed 90% accuracy in the classification of the 
substrates, though of course a different balance between 
sensitivity and specificity could be easily achieved by 
selecting a different score threshold. Cascade application of 
the preceding ensemble together with structure-based 
approaches and a ligand-based classificatory model capable 
of identifying drugs with anticonvulsant effects in the MES 
test (see next section for details on the molecular docking) in 
the virtual screening campaign of ZINC and Drugbank 
databases led to the identification of anticonvulsant 
compounds predicted as non-substrates for Pgp [76]. These 
in silico filters were also applied to an in house library of 
anticonvulsant compounds previously reported by the same 
group, including antimicrobial Propylparaben (compound 
VII) and non-nutritive sweetener potassium Acesulfame 
(compound VIII) [77, 78]. The anticonvulsants discovered 
through this protocol are displayed in (Fig. 4).  
 The same group has recently reported linear model 
ensemble capable of identifying substrates for wild-type 
human ABCG2 [74, 79], which might well be integrated to 
the previously described in silico filters. 
2.2. Structure-based Approaches  
 Structure-based approaches are valuable tools in drug 
design, since they provide atomic details on the interactions 
between the target and ligands. Particularly, docking 
simulations propose possible binding geometries of the 
complexes, and quantify in some way their binding energies 
through their scoring functions. This information allows the 
structural optimization of the ligands to improve their 
interactions with the targets (or to avoid them in antitargets). 
Additionally, docking scores provide a numerical variable to 
discriminate between binders and non-binders (of a defined 
target) in structure-based virtual screening campaigns. 
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Fig. (4). Anticonvulsant drug candidates predicted as non-substrates 
of P-gp by joint application of structure- and ligand-based approaches.  
 
 Regarding P-gp, structure-based methods deal with the 
lack of experimental information about the 3D architecture 
of the human protein. Therefore, the target is usually 
modeled by comparative analysis (homology modeling 
techniques) with templates of mouse P-gp, which shares 
more than 80% of sequence identity with human P-gp [79]. 
The glycoprotein is composed by two sets of transmembrane 
segments (TMs 1-3,6,10,11 and TMs 4,5,7-9,12), which 
generate an internal cavity that contains multiple binding 
sites (Fig. 5) [80 and refs therein]. Experimental data has 
proved the capacity of P-gp to interact at the same time with 
more than one substrate, and the existence of new potential 
sites of interaction with small molecules on the exterior of P-
gp cavity [80]. This information is employed in docking 
protocols to find P-gp substrates/inhibitors. They have, in 
general, less accuracy than ligand-based approaches [81, 75, 
82]. However, there are successful examples in relation to 
the identification of P-gp substrates/inhibitors by means of 
docking simulations, and some of them provide information 
about the conformations of the binders in the active site [79 
and refs therein].  
 To exploit the potentialities of both ligand- and target-
based methods, docking-based filter was coupled a to a 
ligand based search of anticonvulsant compounds with no 
Pgp interactions [76]. As mentioned before, a ligand-based 
model ensemble was initially applied on the ZINC and Drug 
Bank databases, with the aim of identifying new anticonvulsant 
predicted as non-substrates of P-gp. The best 380 candidates 
were then submitted to the docking simulations and the 
compounds presumed with high interaction with the 
glycoprotein were discarded.  
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 The candidates were docked into a homology model of 
human P-gp based on the mouse P-gp structure as template 
(PDB code: 3G61) [80]. Several scoring functions and 
conditions were analyzed to select the best model. The 
abilities of the simulations to reproduce experimental data as 
well to discriminate known P-gp binders from non-binders 
were tested. A flexible receptor model with the scoring 
function of Autodock Vina was able to reproduce 
experimental conformations of mouse P-gp complexes as 
well to predict the 85% of the binders and the 77% of 
nonbinders [80]. Fig. (5) shows the docking solution for the 
binding of Saquinavir to the P-gp active site, as an example 
of the characteristic interactions predicted for known 
binders. The active sites into the P-gp cavity are mostly 
hydrophobic and they are composed by residues with 
lipophilic or aromatic side chains. 
 From the 380 candidates selected by ligand-based 
screening, 275 structures were considered as non-binders by 
docking; evidencing a high level of consensus between both 
protocols. As mentioned before, some of the anticonvulsants 
identified with sequential screening are shown in Fig. (4). 
 
 
 
Fig. (5). Structure of the model of human P-gp colored in green 
with Saquinavir in its predicted binding conformation. Residues of 
the binding pocket are highlighted in green. Carbon atoms of 
Saquinavir are highlighted in cyan.  
 
3. IN VITRO EXPERIMENTAL VALIDATION OF 
THE PREDICTIONS  
 Parent and MDR1 transfected Madin–Darby canine 
kidney epitelial cells were obtained from the Netherlands 
Cancer Institute (Amsterdam, The Netherlands). Cells were 
grown in 25-cm2 culture flasks using DMEM with 10% fetal 
bovine serum, 1% L-glutamine, 1% non-essential amino 
acids and penicillin and streptomycin at 37°C in 5% CO2 
atmosphere. Cells were split twice a week at 70 to 80% 
confluence in a ratio of 1:20 or 1:30 using s Trypsin-EDTA 
solution (0.25%). All transport assays were done with cells 
from passages 19 to 43. Cells were kept at 37°C in 5% CO2. 
 The cells were seeded in 6-well Costar Snapwell plates 
with polycarbonate membrane inserts at a density of 50,000 
cells per insert (1.12 cm2) and grown for 4 days in culture 
medium. The medium was replacing every day. The apical 
media volume was 0.5 ml, and the basal volume was 2 ml. 
Integrity of the cell monolayers was determined by 
measuring the trans-epithelial electrical resistance (TEER, 
Ω.cm2) using an epithelial voltammeter (Millicell-ERS; 
Millipore Corporation). In addition, the integrity was 
checked using Atenolol (ATOL). The apparent permeability 
coefficients (Papp) of Atenolol across MDCK II- MDR I cell 
monolayers were typically 1-5x10-7 cm/s. The expression of 
Pgp was checked by Western Blot analysis and by transports 
assay with Trimethoprim, a substrate for Pgp [83]. 
 On the day of the experiment, culture medium was 
removed, and cells were washed three times with media 
transport (HBSS, Hanks` balance salt solution, pH 7.4, 
Gibco-BRL). The filter inserts containing the cell 
monolayers were placed in an Ussing chamber, and were 
maintained at 37°C and under constant gassing with 
carbogen. Test compounds were added to the donor side (4 
ml for the apical and basal chamber). At 20, 40, 60, 80, 100 
and 120 min, samples (400 µl) were taken from receiver 
compartment followed by addition of 400 µl of transport 
media. For the inhibition experiments, cell monolayers were 
incubated with Amiodarone Chlorhydrate (50 µM) [84] for 1 
h in apical and basolateral chambers before adding the test 
compound.  
 Efflux of Trimethoprim (TMP, 100 µM), Compound 
VIII (Acesulfame, 100 µM), Compound VII 
(Propylparabene, 100 µM), Compound II (2-(2-oxo-2H-
chromen-3-yl)benzoic acid, 2.5 µM) and Compound I (1-
methyl-1,2,3,4'-tetrahidro-1'H-spiro[indol-3,2'-quinazolin]-
2,4'-dione, 1 µM) across the confluent monolayer of cells 
was measured in both directions, i.e., apical to basolateral 
(A-B) and basolateral to apical (B-A) in the presence and 
absence of Amiodarone. Test drugs were dissolved in buffer 
media or propylene glycol (final concentration of 3.5% 
solvent). Apparent permeability (Papp) was calculated with 
the equation Papp = 1/AC0 (dQ/dt), where A is membrane 
surface area (1.12 cm2), C0 is the initial concentration in the 
donor compartment at t=0, and dQ/dt is amount of drug 
transported within a given time period. The net efflux (ER) 
of a test compound was assessed by calculating the ratio of 
Papp in the B-A direction versus Papp in the A-B direction. 
ER= Papp B→A/Papp A→B. 
 For Pgp substrates, the absorption should be decreased 
and the secretion increased in cell lines over-expressing Pgp 
[85]. In the presence of a specific inhibitor for Pgp, the 
ER≈1.  
 The samples were quantified by HPLC system: Dionex 
Ultimate 3000 UHPLC (Thermo Scientific, Sunnyvale, CA) 
configured with a dual gradient tertiary pump (DGP-3000) 
and a DAD-3000 diode array detector. The stationary phase 
was a Phenomenex Luna RP-18 column (150 x 4 mm, 5 µm) 
and the mobile phase was: ATOL: H3PO4 0.1%: Methanol 
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80:20, the flow rate was set at 1 mL/min and detection was 
performed at 225 and 274 nm; TMP: H3PO4 0.1%: Methanol 
65:35, the flow rate was set at 1.3 mL/min and detection was 
performed at 230 and 270 nm; Compound VIII: Buffer 
KH2PO4 20 mM, adjusted to pH 2.5 with H3PO4: Methanol 
80:20, the flow rate was set at 1 mL/min and detection was 
performed at 230 and 240 nm; Compound VII: H3PO4 0.1%: 
Methanol 35:65, the flow rate was set at 1.2 mL/min and 
detection was performed at 230 and 250 nm; Compound II: 
Buffer KH2PO4 20 mM, adjusted to pH 2.5 with H3PO4: 
Methanol 35:65, the flow rate was set at 1 mL/min and 
detection was performed at 220 nm; Compound I: Buffer 
KH2PO4 20 mM, adjusted to pH 2.5 with H3PO4: Methanol 
30:70, the flow rate was set at 1 mL/min and detection was 
performed at 297 nm. 
 Student’s T test for two samples assuming equal 
variances was conducted for statistical comparisons.  
 The values obtained with TMP indicated that the ER 
value is 2.5 times higher in the absence of inhibitor than in 
its presence, demonstrating expression of Pgp. None of the 
four drugs evaluated showed significant differences when 
calculating the ER in presence and absence of Amiodarone 
(Fig. 6), indicating that in the experimental conditions 
studied P-gp efflux does not influence the transport of these 
drugs, which seems consistent with the predictions of the 
models. Nevertheless, it should be noted that compound VIII 
presents an ER significantly different from 1, thus 
suggesting it might be recognized by other efflux 
transporters different than P-gp, which illustrates the 
importance of complementing P-gp models with other 
models to identify efflux by different ABC transporters.  
CONCLUSIONS 
 Though it is unlikely that a single mechanistic hypothesis 
will account for a very complex phenomenon such as multi-
drug resistance, the body of preclinical, clinical and 
pharmacogenomics evidence suggest a role of ABC 
transporters in refractory epilepsy. Most of the studies so far 
have focused on the potential role of P-gp in drug resistant 
epilepsy; while initial studies have disregarded the effect of 
other ABC transporters in epilepsy, such studies should be 
reexamined at the light of recent advances in the field, 
including more recent and complex in vitro and in vivo 
models (e.g. the CETA assay and double and triple knockout 
animal models, which may contribute to explore, 
respectively, the influence of passive diffusion on drug 
permeability and the cooperative function of ABC pumps). 
Despite some existing AEDs are not likely to be transported 
by ABC carriers, current clinical criteria to diagnose 
refractory epilepsy does not actually exclude the possibility 
that a refractory patient could respond to available 
medications: in absence of definitive clinical validation of 
the transporter hypothesis, standard management of epilepsy 
does not consider whether previously administered (and 
unsuccessful) drugs are or are not substrates of ABC 
transporters. Nor does it contemplate assessment of the ABC 
transporters function in a particular patient.  
 In relation to novel therapeutic approaches to drug 
resistant epilepsy, the use of nano-pharmaceutical delivery 
systems and the design of new AEDs which are not 
recognized by ABC transporters (an antitarget approximation) 
represent safer options compared to co-administration of 
ABC transporters inhibitors. These are still, however, 
underexplored alternatives for the management of refractory 
epilepsy. We have discussed a screening protocol based on 
the antitarget approach, which integrates in silico, in vitro 
and in vivo tools to select AED candidates oriented to the 
therapy of drug resistant epilepsy linked to upregulation of 
ABC transporters.  
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Fig. (6). Permeability ratios (B-A/A-P) of the candidate anticonvulsant drugs mentioned. 
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